New hope for advanced stomach cancer patients out of options
NCT ID NCT06948955
Summary
This program provides early access to an investigational drug, bezuclastinib, to be given alongside the existing drug sunitinib for adults with advanced gastrointestinal stromal tumors (GIST). It is for patients whose cancer has progressed after standard treatment and who have no other good therapy choices. The goal is to see if this drug combination can better control the cancer by targeting multiple genetic mutations that drive its growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL NEOPLASMS, GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Foundation
AVAILABLECleveland, Ohio, 44195, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
-
Dana Farber Cancer Institute (DFCI)
AVAILABLEBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
Huntsman Cancer Institute, University of Utah
AVAILABLESalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
AVAILABLEHouston, Texas, 77030, United States
Contact Email: •••••@•••••
-
Mayo Clinic
AVAILABLEJacksonville, Florida, 32224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic
AVAILABLERochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic Hospital
AVAILABLEPhoenix, Arizona, 85054, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
AVAILABLENew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Orlando Health
AVAILABLEOrlando, Florida, 32806, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Smillow Cancer Hospital - Yale New Haven Health
AVAILABLENew Haven, Connecticut, 06510, United States
Contact Email: •••••@•••••
-
Taylor Cancer Research Center
AVAILABLEMaumee, Ohio, 43537, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
AVAILABLEColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
-
The University of Chicago Medical Center
AVAILABLEChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
-
UCLA Department of Medicine- Hematology/Oncology
AVAILABLELos Angeles, California, 90095, United States
Contact Email: •••••@•••••
-
UPMC Hillman Cancer Center
AVAILABLEPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado
AVAILABLEAurora, Colorado, 80045, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.